MDMA’s Advice To FDA On 510(k) Reform: Tone It Down

Rather than take on so much at once, FDA should focus its 510(k) reform efforts on a few initiatives that will have the most bang for the agency’s buck, Medical Device Manufacturers Association’s Mark Leahey says. MDMA’s suggestions? Implement the new “network of experts” program and risk-benefit guidance.

If industry trade group leader Mark Leahey could give FDA one piece of advice as the agency begins another year of 510(k) reform efforts, it would be: Narrow the focus.

According to Leahey, president and CEO of the Medical Device Manufacturers Association, FDA should focus its efforts in 2012 on...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Regulation

More from Policy & Regulation

Numerous Injuries Prompt Class I Recall Of Dexcom CGM Receivers

 

Dexcom has recalled several models of its glucose monitoring receivers due to a speaker glitch that may suppress vital blood sugar alerts. The FDA designated the recall, which affects thousands of devices, as class I.

Experts Call For Database Of Medical Device Labels

 
• By 

A recent JAMA column called for the US FDA to create an online database of medical device labeling, arguing that the move would increase transparency and help researchers, among other benefits. Medtech Insight discussed the idea with the paper’s lead author.

EU Authorities Unite In Call For Urgent Overhaul Of Medtech Regulations

 

EU member states have issued a consensus statement on the urgent need to build momentum to tackle governance and centralization issues as part of much-needed reform of the EU medtech regulatory system.